Table 2.
Mean percentage difference in DPP-4 concentration with and without common endogenous interferents, asthma medications and anti-diabetic medications.
| Interferent | Interferent concentration | Mean % difference in DPP-4 concentration |
|---|---|---|
| Endogenous interferents | ||
| Unconjugated bilirubin | >20 mg/dL | –0.6 |
| Conjugated bilirubin | >20 mg/dL | 4.0 |
| Haemoglobin | >500 mg/dL | –8.0 |
| Total protein | >12,000 mg/dL | 1.0 |
| Triglycerides | >3000 mg/dL | –3.0 |
| Asthma medications | ||
| Salbutamol | 1.67 µmol/L | –0.8 |
| Fluticasone | 345 pg/mL | –0.7 |
| Prednisone | 0.82 µmol/L | –1.8 |
| Desloratidine | 0.97 µmol/L | –3.6 |
| Montelukast | 0.90 µg/mL | 1.7 |
| Ipratropium bromide | 300 pg/mL | –0.2 |
| Cromolyn sodium | 0.03 µg/mL | –0.1 |
| Theophylline | 222 µmol/L | 0.9 |
| Omalizumab | 0.3 mg/mL | –0.1 |
| Anti-diabetic medications | ||
| Vildagliptin (3 X RTD) | 1191 ng/mL | –1.9 |
| Saxagliptin (3 X RTD) | 141 ng/mL | 3.83 |
| Teneligliptin (3 X RTD) | 825 ng/mL | 4.01 |
| Sitagliptin (3 X RTD) | 1439 ng/mL | –56.0 |
| Sitagliptin (2 x RTD) | 720 ng/mL | –30.1 |
| Sitagliptin (1 x RTD) | 480 ng/mL | –4.0 |
DPP-4: dipeptidyl peptidase-4; RTD: recommended therapeutic dosage.